Lv4
590 积分 2024-02-23 加入
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management
15天前
已完结
Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box
15天前
已完结
Breast cancer
15天前
已关闭
Breast cancer
15天前
已完结
The reporting odds ratio and its advantages over the proportional reporting ratio
17天前
已完结
Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database
21天前
已完结
A Case of Semaglutide-Associated Severe AKI in an Immunocompromised Patient
1个月前
已关闭
Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer
1个月前
已完结
Bystander effect of antibody–drug conjugates: fact or fiction?
1个月前
已完结
Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
1个月前
已完结
皖公网安备34019202002308
